Magnetar Financial LLC Takes $3.83 Million Position in Profound Medical Corp. (NASDAQ:PROF)

Magnetar Financial LLC purchased a new stake in Profound Medical Corp. (NASDAQ:PROF - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 509,400 shares of the company's stock, valued at approximately $3,826,000. Magnetar Financial LLC owned about 1.70% of Profound Medical as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Raymond James Trust N.A. boosted its position in shares of Profound Medical by 14.3% in the third quarter. Raymond James Trust N.A. now owns 12,000 shares of the company's stock worth $96,000 after acquiring an additional 1,500 shares during the last quarter. MTM Investment Management LLC raised its stake in Profound Medical by 10.4% during the fourth quarter. MTM Investment Management LLC now owns 18,575 shares of the company's stock worth $139,000 after purchasing an additional 1,750 shares during the period. Vestcor Inc acquired a new position in shares of Profound Medical in the 4th quarter valued at $376,000. Truist Financial Corp purchased a new stake in shares of Profound Medical during the 4th quarter valued at $376,000. Finally, K2 Principal Fund L.P. acquired a new stake in shares of Profound Medical during the 3rd quarter worth $398,000. Hedge funds and other institutional investors own 47.86% of the company's stock.

Profound Medical Trading Down 1.9 %

Shares of PROF traded down $0.13 during trading hours on Tuesday, hitting $6.68. The stock had a trading volume of 64,281 shares, compared to its average volume of 51,708. Profound Medical Corp. has a 12-month low of $5.63 and a 12-month high of $11.42. The firm has a market cap of $200.67 million, a P/E ratio of -4.99 and a beta of 0.78. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.16 and a current ratio of 6.12. The company's fifty day simple moving average is $6.86 and its 200 day simple moving average is $7.40.

Remove Ads

Profound Medical (NASDAQ:PROF - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.11. Profound Medical had a negative return on equity of 85.22% and a negative net margin of 349.41%. The company had revenue of $4.18 million for the quarter, compared to the consensus estimate of $5.92 million. Equities research analysts forecast that Profound Medical Corp. will post -1.12 EPS for the current fiscal year.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.